Departments of 1 Internal Medicine and 2 Medical Physiology, 3 Division of Research and Education, Scott & White Hospital, Texas A&M University System Health Sciences Center, College of Medicine, and 4 Central Texas Veterans Health Care System, Temple, Texas 76504; 5 Department of Internal Medicine, Tohoku University School of Medicine, Aobaku, Sendai, Japan 980-8574; 6 Division of Gastroenterology, University of Rome, La Sapienza, Rome, Italy 00100; 7 Department of Veterinary Pathobiology, Texas A&M University, College Station, Texas, and 8 Department of Morphology and Molecular Pathology, University of Leuven, 3000 Leuven, Belgium
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
To determine the role and
mechanisms of action by which dopaminergic innervation modulates ductal
secretion in bile duct-ligated rats, we determined the expression of
D1, D2, and D3 dopaminergic receptors in cholangiocytes. We evaluated
whether D1, D2 (quinelorane), or D3 dopaminergic receptor agonists
influence basal and secretin-stimulated choleresis and lumen expansion
in intrahepatic bile duct units (IBDU) and cAMP levels in
cholangiocytes in the absence or presence of BAPTA-AM,
chelerythrine, 1-(5-isoquinolinylsulfonyl)-2-methyl piperazine
(H7), or rottlerin. We evaluated whether 1)
quinelorane effects on ductal secretion were associated with increased
expression of Ca2+-dependent PKC isoforms and
2) increased expression of PKC causes inhibition of PKA
activity. Quinelorane inhibited secretin-stimulated choleresis in
vivo and IBDU lumen space, cAMP levels, and PKA activity in
cholangiocytes. The inhibitory effects of quinelorane on
secretin-stimulated ductal secretion and PKA activity were blocked by
BAPTA-AM, chelerythrine, and H7. Quinelorane effects on ductal
secretion were associated with activation of the
Ca2+-dependent PKC- but not other PKC isoforms. The
dopaminergic nervous system counterregulates secretin-stimulated ductal
secretion in experimental cholestasis.
intrahepatic biliary epithelium; bile flow; secretin receptor
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
DUCTAL SECRETION
IS REGULATED by gastrointestinal hormones/peptides (3, 7,
19, 20, 33, 37, 64), bile salts (4), and nerves
(12, 34, 38, 39). Although secretin does not increase bile
flow in normal rats (7, 29, 41), recent studies
(29) have shown that secretin increases biliary bicarbonate in a dose-dependent fashion and is much more effective when
administered via the hepatic artery. In addition to bile duct-ligated
(BDL) rats (7, 24, 43, 64), in which there is enhanced
ductal mass (7), secretin has also been shown to stimulate
bicarbonate secretion in isolated intrahepatic bile duct units (IBDU)
(12) and purified cholangiocytes (9, 41) of
normal rats. The stimulatory effect of secretin on ductal secretion occurs by interaction with receptors expressed only by cholangiocytes (11) through an increase in intracellular cAMP levels
(3, 37, 38, 40, 41, 43, 64), which leads to the opening of
the cystic fibrosis transmembrane conductance regulator (CFTR) channel
(22) and activation of the
Cl/HCO
Cholangiocytes proliferate in response to liver injury/toxins
including BDL (5, 7, 23, 43), partial hepatectomy (41), acute carbon tetrachloride administration
(43), or chronic feeding of -naphthylisothiocyanate
(40) or bile salts (6). Cholangiocyte
proliferation is associated with enhanced basal and secretin-stimulated
ductal secretion (5, 7, 11, 23, 24, 33, 38). The BDL rat
model has been widely used for evaluating basal and secretin-stimulated
ductal secretion (5, 7, 11, 23, 24, 33, 38). In these
studies, we used the BDL rat model, because it allows: 1)
the isolation of a greater number of pure cholangiocytes compared with
normal rats (7, 8) and 2) the in vivo
evaluation of the stimulatory effect of intravenous administration of
secretin on bile flow (7, 8, 38, 43, 64), which is absent
in normal rats (7, 8, 23, 41).
There is growing information regarding the role of nerves in the
regulation of ductal secretion (12, 34, 38, 39). ACh
induces intracellular Ca2+ concentration
([Ca2+]i) increases and oscillation in rat
cholangiocytes due to both influx of extracellular Ca2+ and
mobilization of thapsigargin-sensitive
[Ca2+]i stores (49). Other
studies (12) have shown that ACh, by interaction with M3
ACh receptor subtypes, increases secretin-stimulated Cl/HCO
2-adrenergic receptor agonist
UK-14304 inhibits cholangiocarcinoma growth through time
course-dependent modulation of Raf-1 and B-Raf activities
(34). The
1-adrenergic agonist
phenylephrine potentiates secretin-stimulated ductal secretion through
a Ca2+- and PKC-dependent amplification of the adenylyl
cyclase system (39).
In a number of cells, D1 and D2 dopaminergic receptors modulate
adenylyl cyclase activity with a stimulatory effect mediated by D1
dopaminergic receptors and inhibitory effects regulated by D2
dopaminergic receptors (26, 50, 59), the latter acting through D-myo-inositol-1,4,5-trisphosphate
[Ins(1,4,5)P3] and Ca2+-dependent
intracellular pathways (28). Dopaminergic receptors regulate secretory activity of several epithelia (15, 21, 56). The intrahepatic biliary epithelium displays dopaminergic innervation (45, 46); however, no information exists
regarding the role and mechanisms of action of the dopaminergic system
in the regulation of ductal secretion and adenyl cyclase activity in
cholangiocytes. We addressed the following questions. First, are
functional D1, D2, and D3 dopaminergic receptors expressed by
cholangiocytes? Second, do D1, D2, and D3 dopaminergic receptor agonists/antagonists regulate basal and secretin-stimulated ductal secretion? Third, are dopaminergic effects on ductal bile secretion associated with increased protein expression of
Ca2+-dependent (,
I,
II, and
) and/or
Ca2+-independent novel (
and
) and atypical (
and
) PKC isoforms? Fourth, are quinelorane effects on ductal secretion
associated with cytoskeleton-to-membrane distribution of PKC-
, whose
protein expression is increased by quinelorane? Finally, is increased protein expression of PKC-
(after treatment with a dopaminergic receptor agonist) associated with downregulation of PKA activity leading to inhibition of secretin-stimulated ductal secretion?
![]() |
MATERIALS AND METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Animal Model
Male Fischer 344 rats (150-175 g) were purchased from Charles River (Wilmington, MA). The animals were kept in a temperature-controlled environment (22°C) with a 12:12-h light-dark cycle and fed ad libitum with standard rat chow. The studies were performed in rats with cholangiocyte proliferation induced by BDL (7) [for isolation of cells (5, 18, 23, 24, 38, 43, 64) or IBDU (3, 47, 55)] or bile duct incannulation [BDI, for bile collection (7)] for 1 wk. BDL and BDI were performed as described (7). Before each procedure, animals were anesthetized with pentobarbital sodium (50 mg/kg body wt).Materials
Reagents were purchased from Sigma (St. Louis, MO) unless otherwise indicated. The substrate forPurification of Cholangiocytes
Pure cholangiocytes were obtained from BDL rats by immunoaffinity separation (4-6, 18, 23, 24, 30, 37, 38, 40, 41, 43, 64) by using a mouse monoclonal antibody against an unidentified membrane antigen expressed by all rat intrahepatic cholangiocytes (30). Purity of isolated cholangiocytes was evaluated by histochemistry forExpression of D1, D2, and D3 Dopaminergic Receptors in Purified Cholangiocytes, Liver Sections, and Apical and Basolateral Cholangiocyte Membranes
The expression of D1, D2, and D3 dopaminergic receptors was evaluated by immunoblots in pure cholangiocytes from both normal and BDL rats. The expression of the D2 dopaminergic receptor (the only receptor subtype expressed by cholangiocytes by immunoblots of whole cell lysate) was also determined by immunohistochemistry in liver sections, cytospin smears of pure cholangiocytes, and immunoblots in apical and basolateral cholangiocyte membranes from BDL rats.Immunoblots for D1, D2, or D3 dopaminergic receptors in pure cholangiocytes from BDL rats was performed as follows. Proteins (100 µg) were resolved by SDS-7.5% polyacrylamide gel electrophoresis and transferred onto a nitrocellulose membrane (Bio-Rad, Hercules, CA). The membrane was incubated overnight with rotation at 4°C with a rabbit antibody for the D1, D2, or D3 dopaminergic receptor diluted 1:3,000 with Tris-buffered saline (TBST; 50 mM Tris, 150 mM NaCl, and 0.05% Tween 20)-5% milk. The membrane was washed with TBST and incubated for 1 h at room temperature with a secondary antibody, an anti-rabbit IgG peroxidase conjugate [enhanced chemiluminescence (ECL) kit, Amersham Life Science, Little Chalfont, England] diluted 1:100,000 with TBST. The membrane was washed with TBST, and proteins were visualized by using chemiluminescence (ECL Plus kit, Amersham Life Science). The intensity of the bands was determined by scanning video densitometry by using the ChemiImager 4000 low-light imaging system (Alpha Innotech, San Leandro, CA).
Immunohistochemistry for D2 dopaminergic receptor was performed in fresh frozen liver sections (5-µm thick) from BDL rats. Sections were incubated for 30 min with primary affinity-purified goat polyclonal antibody against the D2 dopaminergic receptor (N-19, Santa Cruz Biotechnology) diluted 1:50. The sections were incubated for 30 min with rabbit-anti-goat antibody (DAKO, Glostrup, Denmark), followed by incubation for 30 min with rabbit EnVision (DAKO). All reagents were diluted in PBS (pH 7.2). Each incubation was followed by a wash in three changes of PBS, pH 7.2, for 15 min. The reaction product was developed with the use of 3-amino-9-ethylcarbazole and H2O2. Sections that were not incubated with a primary antibody served as negative controls. The sections were examined with a microscope (model BX 40; Olympus Optical).
Immunohistochemistry for D2 dopaminergic receptor was performed in cytospin smears of cholangiocytes. Cell smears were fixed with ice-cold acetone for 5 min. After smears were washed with PBS, endogenous peroxidase activity was blocked with 70% methanol containing 3% H2O2. After being blocked with normal rabbit serum, the cells were incubated with the primary antibody (dilution 1:100) at 4°C overnight. After washes with PBS, the conjugated antibody was detected by using a commercially available kit [Histofine SAB-PO(G) kit; Nichirei, Tokyo, Japan] according to the vendor's instructions. The reaction product was visualized with diaminobenzidine. The negative control was performed by using normal goat serum instead of primary antibody.
To determine the subcellular distribution (apical vs. basolateral) of the D2 dopaminergic receptor in cholangiocytes, we evaluated by immunoblots (23) protein expression for the D2 dopaminergic receptor in membranes obtained from the basolateral or apical domain of pure cholangiocytes from BDL rats. Cholangiocyte apical and basolateral membranes were prepared by isopycnic centrifugation on sucrose gradients by using a technique previously used by Tietz et al. (63) in cholangiocytes from BDL rats.
We measured intracellular Ins(1,4,5)P3 and [Ca2+]i levels, second messenger system-activated by D2 dopaminergic innervation (17, 65). Cholangiocytes from BDL rats were incubated for 1 h at 37°C (37) and subsequently stimulated for 15 min at 22°C with 0.2% BSA (basal value) or quinelorane (100 µM) with 0.2% BSA. Intracellular Ins(1,4,5)P3 levels were assessed by the [3H]Ins(1,4,5)P3 kit (Amersham) according to the instructions provided by the manufacturer. Data were expressed as picomoles per million cells.
Calcium fluorescence measurements in purified cholangiocytes from BDL
rats were performed by using fluo 3-AM (Molecular Probes, Eugene,
Oregon) and a microplate reader (Fluoroskan Ascent FL Thermolabsystems,
Helsinki, Finland) equipped with three injectors (36).
Isolated cholangiocytes (4 × 104 per well) were
loaded for 1 h at room temperature with 5 µM of fluo 3-AM in
Tyrode's salt solution (TSS) [(in mM): 137 NaCl, 2.7 KCl, 1 MgCl2, 0.2 NaH2PO4, 12 NaHCO3, and 5.5 glucose] with 0.1% Pluronic F-127
(Molecular Probes). Loaded cells were washed two times with TSS. The
loaded cells were subsequently resuspended in TSS and incubated for an
additional 30 min at room temperature. The loaded cells were then
pelleted and resuspended at 4 × 104 cells per 100 µl of TSS. The 4 × 104 cells per well were added to
a 96-well black microplate. The baseline fluorescence was measured 50 times at 2-s intervals. TSS alone or quinelorane (100 µM) dissolved
in buffer were injected sequentially into separate wells, and the
fluorescence intensity was measured at 538 nm for 3 min at 1-s
intervals. The excitation wavelength was 485 nm.
[Ca2+]i was calculated as follows:
[Ca2+]i = Kd(F Fmin)/(Fmax
F). Fmax is
fluorescence intensity measured after permeabilization of the cells
with 1% NP-40. EGTA (0.1 M) was then added to chelate Ca2+
and minimum fluorescence intensity (Fmin) was obtained. The
Kd of fluo 3-AM was 390 nm (35).
Effect of Dopaminergic Receptor Agonists on Ductal Secretion
Measurement of bile flow, bicarbonate concentration, and secretion. BDI rats were surgically prepared for bile collection (7). One jugular vein was incannulated with a polyethylene-50 cannula to infuse Krebs-Ringer-Henseleit (KRH), secretin, or the selected dopaminergic receptor agonist/antagonist. Body temperature (37°C) was monitored with a rectal thermometer. When steady-state bile flow was achieved (60 min of KRH infusion from the beginning of bile collection), we subsequently infused 1) secretin (100 nM) for 30 min; 2) KRH until steady state; 3) quinelorane (100 µM) for 30 min; 4) KRH; or 5) quinelorane (100 µM) + secretin (100 nM) for 30 min, followed by a final infusion of KRH. In separate experiments, after steady-state bile flow was reached, rats were subsequently infused with 1) secretin (100 nM) for 30 min; 2) KRH until steady state; 3) eticlopride (100 µM) for 30 min; 4) KRH until steady state; or 5) eticlopride (a D2 dopaminergic receptor antagonist; 100 µM) + quinelorane (100 µM) + secretin (100 nM) for 30 min, followed by a final infusion of KRH. We evaluated the effects of a D1 [(±)-SKF-82958 hydrobromide; 100 µM (48)] or a D3 (7-OH-DPAT; 100 nM) (44) dopaminergic receptor agonist on basal and secretin-stimulated bile flow and on bicarbonate concentration and secretion. Bile was collected every 10 min, and bile flow was determined by weight, assuming a density of 1.0 g/ml. Biliary bicarbonate concentration (measured as CO2) was determined in bile by a Natelson microgasometer apparatus (Scientific Industries, Bohemia, NY).
Effect of Quinelorane on Ductal Lumen Expansion in IBDU
IBDU were isolated as described (3, 47, 55). IBDU were incubated for 24 h at 37°C in minimum essential medium (GIBCO-BRL, Grand Island, NY) with 10% fetal calf serum to allow complete sealing of bile duct lumen (3, 47, 55). Ductal fluid secretion was estimated from the changes in the area of IBDU lumen space, as previously described (3, 47, 55), after perfusion with 1) 0.2% BSA (basal); 2) secretin (positive control, 100 nM) (3) with 0.2% BSA; 3) quinelorane (100 µM) in the absence or presence of secretin (100 nM) with 0.2% BSA; or 4) BAPTA-AM (50 µM; an [Ca2+]i chelator) (12, 23), chelerythrine (1 µM) or H7 (20 µM), two Ca2+-dependent PKC inhibitors (23, 32), or rottlerin (10 µM; a Ca2+-independent PKC-Intracellular cAMP Levels in Purified Cholangiocytes
After isolation, pure cholangiocytes from BDL rats were incubated for 1 h at 37°C (37) and subsequently incubated at room temperature (4-6, 18, 23, 24, 37, 38, 40, 41, 43) with 1) 0.2% BSA (basal) for 5 min; 2) secretin (100 nM) with 0.2% BSA for 5 min; 3) quinelorane (100 µM for 5 min) in the absence or presence of secretin (100 nM for 5 min) with 0.2% BSA; 4) eticlopride (100 µM for 5 min) + quinelorane (100 µM for 5 min) + secretin (100 nM for 5 min) with 0.2% BSA; or 5) eticlopride (100 µM for 5 min) in the absence or in the presence of secretin (100 nM for 5 min) with 0.2% BSA. We evaluated the effect of quinelorane (100 µM for 5 min) on secretin-stimulated cAMP levels in the absence or presence of BAPTA-AM (50 µM for 5 min), chelerythrine (1 µM for 5 min), H7 (20 µM for 5 min), or rottlerin (10 µM for 5 min) with 0.2% BSA. We evaluated the effect of BAPTA-AM, H7, chelerythrine, or rottlerin on basal cAMP levels. Intracellular cAMP levels were determined by RIA by using commercially available kits.Are Quinelorane Effects on Secretin-Stimulated Ductal Secretion Associated with Increased Expression of Ca2+-dependent and Ca2+-independent PKC Isoforms?
We evaluated whether the inhibitory effects of quinelorane on secretin-stimulated ductal bile secretion are associated with increased protein expression of Ca2+-dependent (Cholangiocytes were stimulated for 90 min (14, 23) at
37°C with 0.2% BSA (basal) or quinelorane (100 µM) with 0.2% BSA and were subsequently analyzed for protein expression for PKC-, -
I, -
II, -
, -
, -
, -
, -
, and -
by immunoblots
(23). The intensity of the bands was determined by
scanning video densitometry by using the ChemiImager 4000.
Because quinelorane increases only the protein expression for the
Ca2+-dependent PKC-, we then determined whether the
effects of quinelorane on secretin-stimulated ductal secretion were
associated with intracellular redistribution of PKC-
. To achieve
this, we treated in vitro pure cholangiocytes from 1-wk-old BDL rats at
37°C for 90 min (14, 23) with 1) 0.2% BSA
(basal) or 2) quinelorane (100 µM) in 0.2% BSA.
Subsequently, we evaluated protein expression for PKC-
in a
triton-soluble (containing cytoplasm and membrane) fraction and a
triton-insoluble (containing cytoskeleton) fraction by immunoblots
(23). Both triton-soluble and triton-insoluble fractions were obtained from cholangiocytes as described
(14, 23).
Is Quinelorane-Induced Increase in PKC- Protein Expression
Associated with Downregulation of PKA Activity in Cholangiocytes?
Statistical Analysis
All data are expressed as means ± SE. Differences between groups were analyzed by Student's t-test when two groups were analyzed or by ANOVA if more than two groups were analyzed. ![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Cholangiocytes Express D2 Dopaminergic Receptors
Immunoblotting analysis shows that a band (migrating at 55 kDa) (16) for the D2 dopaminergic receptor was expressed by cholangiocytes from both normal and BDL rats (Fig. 1A), whereas D1 and D3 dopaminergic receptors were absent (Fig. 1A). Immunohistochemistry shows positive staining for D2 dopaminergic receptors in liver sections (Fig. 1B) and in cholangiocyte smears from BDL rats (Fig. 1C). Negative controls for D2 dopaminergic receptors for sections and cells from BDL rats are shown in Fig. 1, B and C, respectively. At the subcellular level, we found that a band (migrating at 55 kDa) (16) for the D2 dopaminergic receptor was present in the basolateral but not the apical domain of cholangiocytes (Fig. 1D).
|
Consistent with the concept that cholangiocytes contain functional D2
dopaminergic receptors, quinelorane increased intracellular Ins(1,4,5)P3 levels [0.37 ± 0.059 vs. 0.18 ± 0.018 (basal) pmol/1 × 106 cells, P < 0.05] (Table 1). Parallel with
changes in Ins(1,4,5)P3 levels, quinelorane significantly
(P < 0.05) increased [Ca2+]i
levels of cholangiocytes compared with its corresponding basal value
(Table 1).
|
Quinelorane Inhibits Secretin-Stimulated Bile and Bicarbonate Secretion
Secretin increased bile flow and bicarbonate concentration and secretion compared with its corresponding basal value (Table 2). When infused alone, the D2 dopaminergic receptor agonist quinelorane did not alter basal bile flow and bicarbonate concentration and secretion, but it decreased secretin-stimulated bile flow and bicarbonate concentration and secretion of BDL rats (Table 2). Consistent with the expression of D2 dopaminergic receptors in cholangiocytes, the inhibitory effect of quinelorane on secretin-stimulated bicarbonate-rich choleresis was abolished by eticlopride, a D2 dopaminergic receptor antagonist (Table 2). A potential shortcoming of these in vivo results is that the effect of quinelorane on secretin-stimulated bile flow and bicarbonate secretion of BDL rats (Table 2) may be influenced by the in vivo vascular effects of the D2 dopaminergic receptor agonist quinelorane (53, 66). Eticlopride alone did not alter basal bile flow and bicarbonate concentration and secretion (Table 2). Due to the lack of expression of D1 and D3 dopaminergic receptors, neither (±)-SKF-82958 hydrobromide (a D1 dopaminergic receptor agonist) nor 7-OH-DPAT (a D3 dopaminergic receptor agonist) altered basal or secretin-stimulated bile flow and bicarbonate concentration and secretion (Table 2).
|
Quinelorane Inhibition of Secretin-Stimulated IBDU Lumen Expansion Is Blocked by BAPTA-AM, Chelerythrine, and H7 but not Rottlerin
Secretin increased the area of IBDU luminal spaces in IBDU preparations from BDL rats (Fig. 2). Quinelorane alone did not alter the area of IBDU luminal spaces (Fig. 2A). However, pretreatment of IBDU with quinelorane before the addition of secretin inhibited the stimulatory effect of secretin on the expansion of IBDU luminal spaces (Fig. 2, B-F). The inhibitory effect of quinelorane on secretin-induced ductal lumen expansion was abolished by pretreating purified IBDU with BAPTA-AM (Fig. 2C), chelerythrine (Fig. 2D), and H7 (Fig. 2E) but not rottlerin (Fig. 2F). A possible shortcoming of our studies is represented by the fact that the use of rottlerin excludes the role of PKC-
|
Quinelorane Inhibition of Secretin-Stimulated cAMP Levels Is Blocked by BAPTA-AM, Chelerythrine, and H7 but not Rottlerin
Secretin increased intracellular cAMP levels of cholangiocytes from BDL rats (Fig. 3). Quinelorane alone did not alter basal cAMP levels but inhibited secretin-stimulated cAMP levels of cholangiocytes from BDL rats (Fig. 3). The inhibitory effect of quinelorane on secretin-stimulated cAMP levels was blocked by the D2 dopaminergic receptor antagonist eticlopride (Fig. 3). Consistent with the concept that the Ca2+-dependent PKC system regulates the effects of D2 dopaminergic receptor agonists on cholangiocyte cAMP levels, quinelorane inhibition of secretin-stimulated cAMP synthesis was ablated by BAPTA-AM, chelerythrine, and H7 but not rottlerin (Fig. 3). Due to the lack of expression of D1 and D3 dopaminergic receptors, neither (±)-SKF-82958 hydrobromide (a D1 dopaminergic receptor agonist) nor 7-OH-DPAT (a D3 dopaminergic receptor agonist) altered basal or secretin-stimulated cAMP levels (results not shown).
|
Quinelorane Inhibition of Secretin-Stimulated Ductal Secretion Is
Associated with Increased Protein Expression and Membrane Translocation
of PKC-
|
Similar to that shown in other epithelia (14), PKC-
protein expression in cholangiocytes was significantly higher in the triton-soluble fraction compared with the triton-insoluble fraction (Fig. 4B). Quinelorane induces cytoskeleton-to-membrane
distribution of PKC-
, which was evidenced by increased PKC-
protein expression only in the triton-soluble fraction (Fig.
4B). Consistent with PKC-
translocation to cholangiocyte
membranes, there was a corresponding loss of PKC-
protein expression
in the triton-insoluble fraction of cholangiocytes stimulated with
quinelorane (Fig. 4B).
Quinelorane-Induced Increase in PKC- Expression Is
Associated with Downregulation of PKA Activity in Cholangiocytes
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The present study shows that cholangiocytes express D2 (but not D1
and D3) dopaminergic receptors as demonstrated by immunohistochemistry in liver sections and both immunoblots and immunohistochemistry in
purified cholangiocytes. Immunoblots show that the D2 dopaminergic receptor was present in the basolateral but not the apical domain of
cholangiocyte membranes. Stimulation of D2 dopaminergic receptors with
the D2/D3 dopaminergic receptor agonist quinelorane (27) induces 1) an increase in intracellular
Ins(1,4,5)P3 and Ca2+ levels in purified
cholangiocytes; 2) inhibition of secretin-stimulated bicarbonate-rich choleresis in BDL rats and secretin-induced fluid secretion in IBDU; and 3) inhibition of secretin-induced
cAMP levels and secretin-stimulated PKA activity in purified
cholangiocytes. The inhibitory effects of quinelorane on
secretin-stimulated ductal secretion were blocked by the selective D2
dopaminergic receptor antagonist eticlopride (27, 62),
supporting the concept that quinelorane acts only through D2
dopaminergic receptors in cholangiocytes. These findings indicate that
cholangiocytes express functionally active D2 dopaminergic receptors,
which are involved in the counterregulation of secretin-stimulated,
bicarbonate-rich ductal choleresis. We evaluated the signal
transduction pathways involved in quinelorane inhibition of
secretin-stimulated ductal secretion by demonstrating that
1) quinelorane effects are blocked by BAPTA-AM (a
[Ca2+]i chelator), chelerythrine, and H7 (two
PKC inhibitors) but not rottlerin (a PKC- inhibitor); 2)
quinelorane effects on secretin-stimulated ductal secretion are
associated with increased protein expression of the
Ca2+-dependent PKC-
but not the
Ca2+-independent novel (
,
,
) and atypical (
,
) PKC isoforms; and 3) quinelorane-induced increase in
protein expression and cytoskeleton to membrane distribution of PKC-
was associated with inhibition of secretin-stimulated PKA activity.
A number of studies (12, 34, 38, 49) have shown that the
nervous system is involved in the regulation of cholangiocyte pathophysiology. We have demonstrated (12) that the
cholinergic system regulates cholangiocyte secretory functions. By
acting on M3 ACh receptor subtypes, ACh potentiates secretin-stimulated bicarbonate secretion through an intracellular pathway involving Ca2+, calcineurin, and calmodulin but not PKC
(12). The final target of this pathway is adenylyl
cyclase, whose activity is positively modulated, leading to
amplification of secretin-induced cAMP levels (12). This
results in marked stimulation of CFTR and
Cl/HCO
In this study, we demonstrated that dopaminergic innervation is involved in the counterregulation of secretin-stimulated choleresis. We first demonstrated in bile fistula BDL rats that quinelorane has no effect on basal bile flow and biliary bicarbonate concentration and secretion. However, quinelorane almost completely abolished the stimulatory effect of secretin on bile flow and biliary bicarbonate concentration and secretion. The inhibition of secretin-stimulated choleresis in bile fistula rats could be the consequence of an indirect systemic effect of the dopaminergic system as well as effect on acetylcholine or prolactin release (1, 53, 66, 67). For these reasons, we directly evaluated the effect of quinelorane on isolated IBDU from BDL rats and demonstrated that the expansion of luminal space induced by secretin was completely blocked by quinelorane, indicating a direct action on cholangiocytes by a specific interaction with D2 dopaminergic receptors. This finding was also confirmed in pure cholangiocytes, in which we found that quinelorane (but not D1 or D3 dopaminergic receptor agonists) blocked secretin-stimulated cAMP synthesis.
In IBDU and cholangiocytes, we evaluated the intracellular mechanisms
involved in quinelorane inhibition of secretin-stimulated ductal
secretion. We found that quinelorane increased intracellular cholangiocyte Ins(1,4,5)P3 and Ca2+ levels. In
addition, by the use of the [Ca2+]i chelator
BAPTA-AM, the PKC antagonists chelerythrine and H7, and the
PKC--specific antagonist rottlerin, we provided evidence that
PKC-
plays a role in quinelorane inhibition of secretin-stimulated ductal secretion. This is supported by previous findings showing that,
in many different cell types, D2 dopaminergic receptors are coupled to
Ca2+, Ins(1,4,5)P3, and PKC activation
(17, 52, 60, 65). The intracellular mechanisms by which
quinelorane inhibits secretin-stimulated ductal secretion was
demonstrated in isolated cholangiocytes in which both cAMP levels and
PKA activity induced by secretin were abolished by pretreatment with
quinelorane. This is in keeping with the known functional role of D2,
which is a Gi-coupled receptor whose activation or
overexpression results in the inhibition of adenyl cyclase
activity, as demonstrated in many different central and peripheral
cells (25).
Although the involvement of the PKC pathway in the regulation of cell
function is widely described in different cell types including
cholangiocytes (10, 14, 23, 61, 68), a novel aspect of our
findings is the demonstration that the dopaminergic agonist inhibits
secretin-stimulated ductal secretion by increasing protein expression
and inducing cytoskeleton-to-membrane distribution of PKC-. In
support of the concept that different PKC isoforms can be activated
differentially, we have shown (23) that gastrin inhibits
cholangiocyte proliferation and secretin-stimulated ductal secretion
through activation of PKC-
. Similarly, insulin ursodeoxycholate or
tauroursodeoxycholate inhibition of secretin-stimulated choleresis is associated with activation of PKC-
(2, 42). Feeding
of taurocholate and taurolithocholate to normal rats stimulates
cholangiocyte proliferation and secretin-stimulated secretion through
activation of PKC-
(10). The
1-adrenergic agonist phenylephrine increases secretin-stimulated ductal secretion through a Ca2+- and
PKC-dependent amplification of adenylyl cyclase (39). The
different cross-talk between intracellular Ca2+ and cAMP
(which leads to stimulatory or inhibitory effects on secretin-stimulated ductal secretion) (2, 10, 12, 23, 38, 39,
42) likely depends on the type of receptor [M3 acetylcholine (12), D2 dopaminergic, insulin (42), gastrin
(23), or
1-adrenergic (39)]
or transporter (e.g., Na+-dependent apical bile acid
transporter) (2, 10) that is up- or downregulated. For
example, whereas there is activation of intracellular Ca2+
but not PKC (insensitivity to staurosporine) with acetylcholine (12), there is activation of intracellular
Ins(1,4,5)P3 and Ca2+- and specific isoforms of
PKC with quinelorane (PKC-
), gastrin (PKC-
) (23),
insulin (PKC-
) (42), taurocholate (PKC-
)
(10), ursodeoxycholate (PKC-
) (2), or
tauroursodeoxycholate (PKC-
) (2). Studies aimed to
evaluate the type of PKC isoform activated by the
1-adrenergic receptor agonist phenylephrine are ongoing. These interactions may result in a different cross-talk between [Ca2+]i and specific adenylate cyclase
isoforms, leading to inhibition or stimulation of adenylate cyclase and
of secretin-stimulated ductal secretion.
Thus the dopaminergic system plays a role in the complex mechanisms
regulating the secretory activities of the intrahepatic biliary
epithelium. By opposing the cholinergic system (which potentiates
secretin-stimulated ductal secretion and adenylate cyclase activity)
(12), the dopaminergic system inhibits secretin-induced choleresis through inhibition of adenylate cyclase activity. Although both systems exert their functions through increased intracellular Ins(1,4,5)P3 and Ca2+, the cholinergic system
acts via calmodulin and calcineurin but without recruitment of PKC
(12), whereas the D2 dopaminergic system inhibits
secretin-stimulated ductal secretion by increasing protein expression
and inducing cytoskeleton-to-membrane distribution of PKC-. However,
a possible shortcoming of our studies is that we would like to
emphasize that PKC-
may be not the only player in the regulation of
dopaminergic effects on secretin choleresis and that other PKC isoforms
(e.g.,
,
1,
2,
,
,
,
, and
), although
decreased or unchanged by quinelorane, may have a role in dopaminergic
regulation of secretin-stimulated ductal secretion. Our studies have
pathophysiological implications, because modulation of the dopaminergic
system may play an important role in the regulation of cholangiocyte
proliferation and ductal secretion in cholestatic liver diseases. This
concept is supported by studies showing that 1) ACh
potentiates secretin-stimulated ductal bicarbonate secretion
(12); 2) interruption of the parasympathetic
system (by vagotomy) inhibits cholangiocyte proliferation and
secretin-stimulated choleresis of BDL rats (38); and
3) proliferating cholangiocytes acquire phenotypic features
of neuroendocrine tissue and expresses the neural adhesion molecule
(57).
![]() |
ACKNOWLEDGEMENTS |
---|
We thank S. Ambrus for technical assistance with immunohistochemistry.
![]() |
FOOTNOTES |
---|
This work was supported by a Scott & White Hospital grant and the Texas A&M University System (to G. LeSage and G. Alpini), by a Scott & White Hospital grant (to S. Glaser), by National Institute of Diabetes and Digestive and Kidney Diseases Grant DK-54208 (to G. LeSage), by a Veterans Affairs Merit Award and National Institute of Diabetes and Digestive and Kidney Diseases Grant DK-58411 (to G. Alpini), and by MURST Grant MM06215421/2 progetto nazionale 2000 (to D. Alvaro).
Address for reprint requests and other correspondence: G. Alpini, Associate Professor, Internal Medicine and Medical Physiology, The Texas A&M University System, Health Sciences Center COM and Central Texas Veterans Health Care System, 702 SW H. K. Dodgen Loop, Temple, TX 76504 (E-mail: galpini{at}tamu.edu).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
First published December 27, 2002;10.1152/ajpgi.00302.2002
Received 25 July 2002; accepted in final form 6 December 2002.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1.
Acquas, E,
and
Fibiger HC.
Dopaminergic regulation of striatal acetylcholine release: the critical role of acetylcholinesterase inhibition.
J Neurochem
70:
1088-1093,
1998[ISI][Medline].
2.
Alpini, G,
Baiocchi L,
Glaser S,
Ueno Y,
Marzioni M,
Francis H,
Phinizy JL,
Angelico M,
and
LeSage G.
Ursodeoxycholate and tauroursodeoxycholate inhibit cholangiocyte growth and secretion of BDL rats through activation of PKC alpha.
Hepatology
35:
1041-1052,
2002[ISI][Medline].
3.
Alpini, G,
Glaser S,
Robertson W,
Rodgers RE,
Phinizy JL,
Lasater J,
and
LeSage GD.
Large but not small intrahepatic bile ducts are involved in secretin-regulated ductal bile secretion.
Am J Physiol Gastrointest Liver Physiol
272:
G1064-G1074,
1997
4.
Alpini, G,
Glaser SS,
Rodgers R,
Phinizy JL,
Robertson WE,
Lasater J,
Caligiuri A,
Tretjak Z,
and
LeSage GD.
Functional expression of the apical Na+-dependent bile acid transporter in large but not small rat cholangiocytes.
Gastroenterology
113:
1734-1740,
1997[ISI][Medline].
5.
Alpini, G,
Glaser SS,
Ueno Y,
Pham L,
Podila PV,
Caligiuri A,
LeSage G,
and
LaRusso NF.
Heterogeneity of the proliferative capacity of rat cholangiocytes after bile duct ligation.
Am J Physiol Gastrointest Liver Physiol
274:
G767-G775,
1998
6.
Alpini, G,
Glaser SS,
Ueno Y,
Rodgers R,
Phinizy JL,
Francis H,
Baiocchi L,
Holcomb LA,
Caligiuri A,
and
LeSage GD.
Bile acid feeding induces cholangiocyte proliferation and secretion: evidence for bile acid-regulated ductal secretion.
Gastroenterology
116:
179-186,
1999[ISI][Medline].
7.
Alpini, G,
Lenzi R,
Sarkozi L,
and
Tavoloni N.
Biliary physiology in rats with bile ductular cell hyperplasia. Evidence for a secretory function of proliferated bile ductules.
J Clin Invest
81:
569-578,
1988[ISI][Medline].
8.
Alpini, G,
Lenzi R,
Zhai WR,
Slott PA,
Liu MH,
Sarkozi L,
and
Tavoloni N.
Bile secretory function of intrahepatic biliary epithelium in the rat.
Am J Physiol Gastrointest Liver Physiol
257:
G124-G133,
1989
9.
Alpini, G,
Roberts S,
Kuntz SM,
Ueno Y,
Gubba S,
Podila PV,
LeSage G,
and
LaRusso NF.
Morphological, molecular, and functional heterogeneity of cholangiocytes from normal rat liver.
Gastroenterology
110:
1636-1643,
1996[ISI][Medline].
10.
Alpini, G,
Ueno Y,
Glaser SS,
Marzioni M,
Phinizy JL,
Francis H,
and
LeSage G.
Bile acid feeding increased proliferative activity and apical bile acid transporter expression in both small and large rat cholangiocytes.
Hepatology
34:
868-876,
2001[ISI][Medline].
11.
Alpini, G,
Ulrich CD, II,
Phillips JO,
Pham LD,
Miller LJ,
and
LaRusso NF.
Upregulation of secretin receptor gene expression in rat cholangiocytes after bile duct ligation.
Am J Physiol Gastrointest Liver Physiol
266:
G922-G928,
1994
12.
Alvaro, D,
Alpini G,
Jezequel AM,
Bassotti C,
Francia C,
Fraioli F,
Romeo R,
Marucci L,
LeSage G,
Glaser SS,
and
Benedetti A.
Role and mechanisms of action of acetylcholine in the regulation of rat cholangiocyte secretory functions.
J Clin Invest
100:
1349-1362,
1997
13.
Alvaro, D,
Mennone A,
and
Boyer JL.
Role of kinases and phosphatases in the regulation of fluid secretion and Cl/HCO
14.
André, F,
Rigot V,
Remacle-Bonnet M,
Luis J,
Pommier G,
and
Marvaldi J.
Protein kinase C- and -
are involved in insulin-like growth factor-I migration of colonic epithelial cells.
Gastroenterology
116:
64-77,
1999[ISI][Medline].
15.
Barton, AC,
and
Sibley DR.
Agonist-induced desensitization of D1-dopamine receptors linked to adenylyl cyclase activity in cultured NS20Y neuroblastoma cells.
Mol Pharmacol
38:
531-541,
1990[Abstract].
16.
Beischlag, TV,
Marchese A,
Meador-Woodruff JH,
Damask SP,
O'Dowd BF,
Tyndale RF,
van Tol HH,
Seeman P,
and
Niznik HB.
The human dopamine D5 receptor gene: cloning and characterization of the 5'-flanking and promoter region.
Biochemistry
34:
5960-5970,
1995[ISI][Medline].
17.
Bofill-Cardona, E,
Kudlacek O,
Yang Q,
Ahorn H,
Freissmuth M,
and
Nanoff C.
Binding of calmodulin to the D2-dopamine receptor reduces receptor signaling by arresting the G protein activation switch.
J Biol Chem
275:
32672-32680,
2000
18.
Caligiuri, A,
Glaser S,
Rodgers RE,
Phinizy JL,
Robertson W,
Papa E,
Pinzani M,
and
Alpini G.
Endothelin-1 inhibits secretin-stimulated ductal secretion by interacting with ETA receptors on large cholangiocytes.
Am J Physiol Gastrointest Liver Physiol
275:
G835-G846,
1998
19.
Cho, WK,
and
Boyer JL.
Vasoactive intestinal polypeptide is a potent regulator of bile secretion from rat cholangiocytes.
Gastroenterology
117:
420-428,
1999[ISI][Medline].
20.
Cho, WK,
Mennone A,
Ryderg SA,
and
Boyer JL.
Bombesin stimulates bicarbonate secretion from rat cholangiocytes: implications for neural regulation of bile secretion.
Gastroenterology
113:
311-321,
1995.
21.
Enjalbert, A,
and
Bockaert J.
Pharmacological characterization of the D2 dopamine receptor negatively coupled with adenylate cyclase in rat anterior pituitary.
Mol Pharmacol
23:
576-584,
1983[Abstract].
22.
Fitz, JG,
Basavappa S,
McGill J,
Melhus O,
and
Cohn JA.
Regulation of membrane chloride currents in rat bile duct epithelial cells.
J Clin Invest
91:
319-328,
1993[ISI][Medline].
23.
Glaser, S,
Benedetti A,
Marucci L,
Alvaro D,
Baiocchi L,
Kanno N,
Caligiuri A,
Phinizy JL,
Chowdury U,
Papa E,
LeSage G,
and
Alpini G.
Gastrin inhibits cholangiocyte growth in bile duct-ligated rats by interaction with cholecystokinin-B/gastrin receptors via D-myo-inositol 1,4,5-triphosphate-, Ca(2+)-, and protein kinase C alpha-dependent mechanisms.
Hepatology
32:
17-25,
2000[ISI][Medline].
24.
Glaser, SS,
Rodgers R,
Phinizy JL,
Robertson WE,
Lasater J,
Caligiuri A,
Tretjak Z,
LeSage G,
and
Alpini G.
Gastrin inhibits secretin-induced ductal secretion by interaction with specific receptors on rat cholangiocytes.
Am J Physiol Gastrointest Liver Physiol
273:
G1061-G1070,
1997
25.
Gordon, AS,
Yao L,
Jiang Z,
Fishburn CS,
Fuchs S,
and
Diamond I.
Ethanol acts synergistically with a D2 dopamine agonist to cause translocation of protein kinase C.
Mol Pharmacol
59:
153-160,
2001
26.
Hayes, G,
Biden TJ,
Selbie LA,
and
Shine J.
Structural subtypes of the dopamine D2 receptor are functionally distinct: expression of the cloned D2A and D2B subtypes in a heterologous cell line.
Mol Endocrinol
6:
920-926,
1992[Abstract].
27.
Hemmati, P,
Shilliam CS,
Hughes ZA,
Shah AJ,
Roberts JC,
Atkins AR,
Hunter AJ,
and
Heidbreder CA.
In vivo characterization of basal amino acid levels in subregions of the rat nucleus accumbens: effect of a dopamine D(3)/D(2) agonist.
Neurochem Int
39:
199-208,
2001[ISI][Medline].
28.
Hernandez-Lopez, S,
Tkatch T,
Perez-Garci E,
Galarraga E,
Bargas J,
Hamm H,
and
Surmeier DJ.
D2 dopamine receptors in striatal medium spiny neurons reduce L-type Ca2+ currents and excitability via a novel PLC(beta)1-IP3-calcineurin-signaling cascade.
J Neurosci
20:
8987-8995,
2000
29.
Hirata, K,
and
Nathanson MH.
Bile duct epithelia regulate biliary bicarbonate excretion in normal rat liver.
Gastroenterology
121:
396-406,
2001[ISI][Medline].
30.
Ishii, M,
Vroman B,
and
LaRusso NF.
Isolation and morphological characterization of bile duct epithelial cells from normal rat liver.
Gastroenterology
97:
1236-1247,
1989[ISI][Medline].
31.
Izquierdo-Claros, RM,
Boyano-Adanez MC,
Larsson C,
Gustavsson L,
and
Arilla E.
Acute effects of D1- and D2-receptor agonist and antagonist drugs on somatostatin binding, inhibition of adenylyl cyclase activity and accumulation of inositol 1,4,5-trisphosphate in the rat striatum.
Brain Res Mol Brain Res
47:
99-107,
1997[ISI][Medline].
32.
Jones, BA,
Rao YP,
Stravitz RT,
and
Gores GJ.
Bile salt-induced apoptosis of hepatocytes involves activation of protein kinase C.
Am J Physiol Gastrointest Liver Physiol
272:
G1109-G1115,
1997
33.
Kanno, N,
LeSage G,
Glaser S,
and
Alpini G.
Regulation of cholangiocyte bicarbonate secretion.
Am J Physiol Gastrointest Liver Physiol
281:
G612-G625,
2001
34.
Kanno, N,
LeSage G,
Phinizy JL,
Glaser S,
Francis H,
and
Alpini G.
Stimulation of alpha2-adrenergic receptor inhibits cholangiocarcinoma growth through modulation of Raf-1 and B-Raf activities.
Hepatology
35:
1329-1340,
2002[ISI][Medline].
35.
Kao, J.
Practical aspects of measuring [Ca2+] with fluorescent indicators.
Methods Cell Biol
40:
155-181,
1994[ISI][Medline].
36.
Kassack, M,
Hofgen B,
Lehmann J,
Eckstein N,
Quillan J,
and
Sadee W.
Functional screening of G protein-coupled receptors by measuring intracellular calcium with a fluorescence microplate reader.
J Biomolecular Screening
7:
233-246,
2002[ISI].
37.
Kato, A,
Gores GJ,
and
LaRusso NF.
Secretin stimulates exocytosis in isolated bile duct epithelial cells by a cyclic AMP-mediated mechanism.
J Biol Chem
267:
15523-15529,
1992
38.
LeSage, EG,
Alvaro D,
Benedetti A,
Glaser S,
Marucci L,
Baiocchi L,
Eisel W,
Caligiuri A,
Phinizy JL,
Rodgers R,
Francis H,
and
Alpini G.
Cholinergic system modulates growth, apoptosis, and secretion of cholangiocytes from bile duct-ligated rats.
Gastroenterology
117:
191-199,
1999[ISI][Medline].
39.
LeSage, G,
Glaser S,
Alvaro D,
Marzioni M,
Ueno Y,
Francis H,
and
Alpini G.
Alpha-1 (but not beta-1) adrenergic agonists potentiate secretin-stimulated ductal secretion in bile duct ligated (BDL) rats through cross-talk between Ca2+-dependent PKC and adenylyl cyclase pathways (Abstract).
Hepatology
34:
A1219,
2001.
40.
LeSage, G,
Glaser S,
Ueno Y,
Alvaro D,
Baiocchi L,
Kanno N,
Phinizy JL,
Francis H,
and
Alpini G.
Regression of cholangiocyte proliferation after cessation of ANIT feeding is coupled with increased apoptosis.
Am J Physiol Gastrointest Liver Physiol
281:
G182-G190,
2001
41.
LeSage, G,
Glaser SS,
Gubba S,
Robertson WE,
Phinizy JL,
Lasater J,
Rodgers RE,
and
Alpini G.
Regrowth of the rat biliary tree after 70% partial hepatectomy is coupled to increased secretin-induced ductal secretion.
Gastroenterology
111:
1633-1644,
1996[ISI][Medline].
42.
LeSage, G,
Marucci L,
Alvaro D,
Glaser S,
Marzioni M,
Patel T,
Francis H,
Phinizy JL,
and
Alpini G.
Insulin inhibits secretin-induced ductal secretion by activation of PKC alpha and inhibition of PKA activity.
Hepatology
36:
641-651,
2002[ISI][Medline].
43.
LeSage, GD,
Glaser SS,
Marucci L,
Benedetti A,
Phinizy JL,
Rodgers R,
Caligiuri A,
Papa E,
Tretjak Z,
Jezequel AM,
Holcomb LA,
and
Alpini G.
Acute carbon tetrachloride feeding induces damage of large but not small cholangiocytes from BDL rat liver.
Am J Physiol Gastrointest Liver Physiol
276:
G1289-G1301,
1999
44.
Maj, J,
Rogoz Z,
and
Skuza G.
The anticataleptic effect of 7-OH-DPAT: are dopamine D3 receptors involved?
J Neural Transm
106:
1063-1073,
1999[ISI].
45.
Mann, R,
Bhathal PS,
and
Bell C.
Aminergic innervation of the gall bladder in man and dog.
Clin Auton Res
1:
205-213,
1991[Medline].
46.
Mann, R,
Bhathal PS,
and
Bell C.
Sympathetic innervation of the liver in man and dog: an immunohistochemical study.
Clin Auton Res
1:
141-145,
1991[Medline].
47.
Mennone, A,
Alvaro D,
Cho W,
and
Boyer JL.
Isolation of small polarized bile duct units.
Proc Natl Acad Sci USA
92:
6527-6531,
1995[Abstract].
48.
Murray, AM,
and
Waddington JL.
The induction of grooming and vacuous chewing by a series of selective D-1 dopamine receptor agonists: two directions of D1:D2 interaction.
Eur J Pharmacol
160:
377-384,
1989[ISI][Medline].
49.
Nathanson, MH,
Burgstahler AD,
Mennone A,
and
Boyer JL.
Characterization of cytosolic Ca2+ signaling in rat bile duct epithelia.
Am J Physiol Gastrointest Liver Physiol
271:
G86-G96,
1996
50.
Ng, GY,
Trogadis J,
Stevens J,
Bouvier M,
O'Dowd BF,
and
George SR.
Agonist-induced desensitization of dopamine D1 receptor-stimulated adenylyl cyclase activity is temporally and biochemically separated from D1 receptor internalization.
Proc Natl Acad Sci USA
92:
10157-10161,
1995[Abstract].
51.
Noh, JS,
and
Gwag BJ.
Attenuation of oxidative neuronal necrosis by a dopamine D1 agonist in mouse cortical cell cultures.
Exp Neurol
146:
604-608,
1997[ISI][Medline].
52.
Nowicki, S,
Kruse MS,
Brismar H,
and
Aperia A.
Dopamine-induced translocation of protein kinase C isoforms visualized in renal epithelial cells.
Am J Physiol Cell Physiol
279:
C1812-C1818,
2000
53.
Quevedo, M,
Prieto JC,
and
Perez-Olea J.
The effect of fenoldopam on the blood pressure of the rat.
Gen Pharmacol
32:
123-125,
1999[Medline].
54.
Reyland, ME,
Anderson SM,
Matassa AA,
Barzen KA,
and
Quissell DO.
Protein kinase C delta is essential for etoposide-induced apoptosis in salivary gland acinar cells.
J Biol Chem
274:
19115-19123,
1999
55.
Roberts, S,
Kuntz S,
Gores G,
and
LaRusso N.
Regulation of bicarbonate-dependent ductular secretion assessed by lumenal micropuncture of isolated rodent intrahepatic bile ducts.
Proc Natl Acad Sci USA
90:
9080-9084,
1993[Abstract].
56.
Roberts-Lewis, JM,
Roseboom PH,
Iwaniec LM,
and
Gnegy ME.
Differential downregulation of D1-stimulated adenylate cyclase activity in rat forebrain after in vivo amphetamine treatments.
J Neurosci
6:
2245-2251,
1986[Abstract].
57.
Roskams, T,
De Vos R,
and
Desmet V.
`Undifferentiated progenitor cells' in focal nodular hyperplasia of the liver.
Histopathology
28:
291-299,
1996[ISI][Medline].
58.
Rutemburg, AM,
Kim H,
Fischbein JW,
Hanker JS,
Wasserkrug HL,
and
Seligman AM.
Histochemical and ultrastructural demonstration of gamma-glutamyl transpeptidase activity.
J Histochem Cytochem
17:
517-526,
1969[ISI][Medline].
59.
Senogles, SE.
The D2 dopamine receptor isoforms signal through distinct Gi proteins to inhibit adenylyl cyclase.
J Biol Chem
269:
23120-23127,
1994
60.
Senogles, SE.
The D2s dopamine receptor stimulates phospholipase D activity: a novel signaling pathway for dopamine.
Mol Pharmacol
58:
455-462,
2000
61.
Shanmugam, M,
Krett NL,
Maizels ET,
Cutler REJ,
Peters CA,
Smith LM,
O'Brien ML,
Park-Sarge OK,
Rosen ST,
and
Hunzicker-Dunn M.
Regulation of protein kinase C delta by estrogen in the MCF-7 human breast cancer cell line.
Mol Cell Endocrinol
148:
109-118,
1999[ISI][Medline].
62.
Svenningsson, P,
Lindskog M,
Ledent C,
Parmentier M,
Greengard P,
Fredholm BB,
and
Fisone G.
Regulation of the phosphorylation of the dopamine- and cAMP-regulated phosphoprotein of 32 kDa in vivo by dopamine D1, dopamine D2, and adenosine A2A receptors.
Proc Natl Acad Sci USA
97:
1856-1860,
2000
63.
Tietz, P,
Levine S,
Holman R,
Fretham C,
and
LaRusso NF.
Characterization of apical and basolateral plasma membrane domains derived from cultured rat cholangiocytes.
Anal Biochem
254:
192-199,
1997[ISI][Medline].
64.
Tietz, PS,
Alpini G,
Pham LD,
and
LaRusso NF.
Somatostatin inhibits secretin-induced ductal hypercholeresis and exocytosis by cholangiocytes.
Am J Physiol Gastrointest Liver Physiol
269:
G110-G118,
1995
65.
Vallar, L,
and
Meldolesi J.
Mechanisms of signal transduction at the dopamine D2 receptor.
Trends Pharmacol Sci
10:
74-77,
1989[ISI][Medline].
66.
Vegh, A,
Papp JG,
Semeraro C,
Fatehi-Hasanabad Z,
and
Parratt JR.
The dopamine receptor agonist Z1046 reduces ischaemia severity in a canine model of coronary artery occlusion.
Eur J Pharmacol
344:
203-213,
1998[ISI][Medline].
67.
Verbeeck, WJ,
Berk M,
Paiker J,
and
Jersky B.
The prolactin response to sulpiride in major depression: the role of the D2 receptor in depression.
Eur Neuropsychopharmacol
11:
215-220,
2001[ISI][Medline].
68.
Zhu, GH,
Wong BC,
Slosberg ED,
Eggo MC,
Ching CK,
Yuen ST,
Lai KC,
Soh JW,
Weinstein IB,
and
Lam SK.
Overexpression of protein kinase C-beta1 isoenzyme suppresses indomethacin-induced apoptosis in gastric epithelial cells.
Gastroenterology
118:
507-514,
2000[ISI][Medline].